Bluebird bio Inc

NASDAQ:BLUE  
5.63
-0.34 (-5.70%)
5:23:16 PM EDT: $5.61 -0.02 (-0.36%)
Products

FDA Granted Approval Of Zynteglo To Bluebird Bio, Inc.

Published: 08/17/2022 17:51 GMT
Bluebird bio Inc (BLUE) - FDA Approves First Cell-based Gene Therapy to Treat Adult and Pediatric Patients With Beta-thalassemia Who Require Regular Blood Transfusions.
FDA - Approved Zynteglo (betibeglogene Autotemcel).